Expertise in
17
conditions

Morihito Okada

Minami, JP 
Expertise in
17
conditions
Minami, JP 

Overview

Morihito Okada practices practicing medicine in Minami, Japan.

Okada is highly rated in 17 conditions, according to our data. Their clinical expertise encompasses Lung Adenocarcinoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mastectomy, and Tissue Biopsy.

They are actively involved in clinical research, co-authoring 551 peer reviewed articles and participating in 3 clinical trials.

Locations

Minami, 7348551, Japan
Other Locations
Hiroshima, Japan
Tokyo, 1040045, Japan
Kyoto, Japan
Horoshima, Japan
Suita, Japan
Yamagata, Japan
Higashihiroshima, Japan
Nagoya, Japan
Miemachi, Japan
Nagano, 3818551, Japan
Osaka, Japan
Takatsuki, Japan
Towada, Japan
Ube, 7558505, Japan
Tsu, Japan
Niigata, Japan
Kurashiki, Japan
Yamaguchi, Japan
Wakayama, Japan
Nata, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
View 2 Less Clinical Trials

551 Total Publications

Correction: Immunological impact of tumor-draining lymph node dissection on systemic Th1-like CD4+ T cells in patients with early-stage lung cancer.
Correction: Immunological impact of tumor-draining lymph node dissection on systemic Th1-like CD4+ T cells in patients with early-stage lung cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: August 01, 2026

Frequently Asked Questions about Morihito Okada

Is Morihito Okada a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Morihito Okada is classified as an Elite expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Morihito Okada participate in research or clinical trials?

Yes. Morihito Okada has published 551 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Morihito Okada's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Okada's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile